Key Takeaways
- Profitability surged despite volume headwinds: Q2 FY27 EBITDA grew ~58% YoY to ₹106 crores on a 36% revenue rise, with margins expanding to 22% from 19%, even as H1 aggregate volumes fell 14% YoY versus H1 FY26.
- Sequential margin compression is a mix story, not a demand signal: EBITDA moderated from 26% in Q1 to 22% in Q2, driven by raw material price spikes (methanol at ₹61–62 vs normal ₹26–30, ammonia at ₹85–90 vs normal ₹45–50) that management calls mediator-driven and geopolitically amplified.
- The expansion pipeline is now fully loaded: Acetonitrile at 1,440 tons/month, DME commercial production, brownfield EDA derivatives, and greenfield sodium cyanide/EDTA all target commissioning by FY27-end, setting up a step-change in addressable volumes from Q1 FY28, with management expecting plants to reach 80–90% utilization.
- Management is deliberately deferring capacity bets: Despite customer pull for additional DMC and other carbonates, the company will not commit fresh capex until existing capacity utilization proves out, citing its own 20–30% utilization versus 80–90% projections.
- What to watch next quarter: Whether Acetonitrile hits the promised 1,000–1,200 tons/month from December, DMC/PC deliveries begin at 500–1,000 tons, and raw material prices show any normalization from current elevated levels.
Volume Ramp & Capacity Utilization
- DMF recovery underway: Plant utilization improved from 30–40% to over 50% because DMF basic prices have moved above ₹110–115; management believes if the price trend holds, Unit-4 methylamine will run at 70–80% capacity.
- Methylamine Unit-4 still in early ramp: Currently at only 15–20% utilization, with the 70–80% target contingent on sustained DMF pricing.
- DMC/PC inflection point: A client has stepped up ask from 20–60 tons to 500–1,000 tons this quarter, with deliveries expected from next month onwards, marking the first material volume commitment for this product line.
- EDA running at half potential: Utilization at 50–60% with price improvements noted, but the antidumping duty that could have accelerated offtake was recommended by the Commerce Ministry and blocked by the Finance Ministry, an impasse the company is now litigating.
- Acetonitrile at full throttle imminent: The process-improved plant with 1,440 tons/month capacity will go "in full swing" within 2–3 weeks; management commits to minimum 1,000–1,200 tons every month from December, subject to market acceptance.
- DME early-stage but export traction visible: 7–8 ISO tanks exported on a repeated basis for aerosol applications internationally, plus 20–25 cylinders sold domestically; bulk supplies await Road Tankers approval (expected in 3–4 weeks) and BPCL's Government of India blending permission.
- Brownfield expansion deliberately staggered: Management is running the plant 10–15 days and doing expansion works 10–15 days per cycle rather than a full shutdown, prioritizing market presence and demand capture over speed; one final stoppage cycle runs from 10th December to month-end for finishing modifications.
D Ram Reddy: "If I close the plant, that Unit 1 for this brownfield expansion, you will not see any sales... if I not do all these things, then I would have done by July, August, we would have done that. But what is the use that if you are not taking the advantage of the market."
Raw Material Volatility & Margin Mechanics
- Methanol and ammonia prices have spiked: Methanol at ₹61–62 versus a normal range of ₹26–30, ammonia at ₹85–90 versus ₹45–50, driven by geopolitical disruptions (war, sanctions) and what management describes as opportunistic mediator behavior that decouples pricing from cost.
- Sequential margin compression explained: The 400 bps QoQ EBITDA margin decline from 26% to 22% reflects these input cost spikes flowing through, partially offset by product mix management and operating efficiencies that protected YoY profitability.
- Volume strategy adapts to volatility: Management is booking orders rather than building inventory in this environment, which keeps volumes lower than potential but protects against raw material price risk.
- Normalization assumed, not guaranteed: Management expects prices to come down with marginal increments if the situation normalizes, with a normal year-on-year increase of 7–8%, but expresses uncertainty about when mediator behavior returns to rational levels.
D Ram Reddy: "Simply today, somebody says that there's a bomb blast, immediately, they will increase the prices without looking into their cost price, they will double the prices. That is the situation currently. And sometimes we are worried whether this type of attitude will come to the normal for the mediators in the coming months, we do not know."
Expansion Pipeline: The FY27-End Inflection
- Three-project concurrency at Balaji Specialty Chemicals: Unit-1 brownfield (EDA-based derivatives: DETA, TETA, Piperazine, AEEA, AEP) targets commissioning towards end of FY27; Unit-2 greenfield (hydrogen cyanide, sodium cyanide, EDTA, EDTA-2Na) at MIDC Chincholi targets Q4 FY27; N-Methyl Morpholine commercialization also targeted during FY27.
- Brownfield Unit-1 product expected January: If everything goes well, product should enter the market from January; any delay in 1–2 equipment items could push to February or March first week.
- All capex closes this financial year: Management states that by end of FY27, all expansions and capital investment will be completed; from Q1 FY28, the focus shifts entirely to capacity utilization, with all plants targeting 80–90% utilization for one product or another.
- Topline aspiration anchored to execution: ₹3,500–4,000 crores by FY28–29 assumes all expansions (Acetonitrile full swing, DME full swing, DMF, NMM, both subsidiary projects) commence commercial production by FY28–29; management believes this range is reachable even if prices decline modestly.
- DME utilization has a binary catalyst: If BPCL receives Government of India approval for LPG blending, DME capacity utilization exceeds 90% next year; without it, management still expects at least 50–55% from aerosol exports and domestic offtake.
Product-Level Dynamics & Regulatory Friction
- EDA antidumping deadlock: The Commerce Ministry recommended antidumping duty, finding clear evidence of dumping, but the Finance Ministry did not implement it; the company is preparing a writ petition to approach the High Court, likely filing within one month, following the path other affected companies have taken.
- DME regulatory approvals progressing: PESO Road Tanker valves approval was completed this quarter; Road Tankers approval is at an advanced stage and expected in the next 3–4 weeks, which will unlock bulk domestic supplies.
- DME LPG blending economics hinge on methanol: Management expects methanol to decline below ₹80, which would make DME much more competitive versus LPG and strengthen the blending proposition.
- Acetonitrile pricing question left unanswered: An analyst asked what pricing to assume for the expanded Acetonitrile capacity (₹240 per kg for the entire 1,440 tons/month), but the moderator cut off the question before management could respond.
- DME revenue recognition undisclosed: Management described DME volumes (exports and domestic cylinders) but did not provide a revenue figure when asked, and the Q&A session was closed immediately after.
D Ram Reddy: "One side, government is talking about the Make in India, Atmanirbhar Bharat, but other side, they are not supporting specifically, Finance Department is not supporting. I don't know what went wrong with them because it's a clear case, the government has clearly mentioned, Ministry of Commerce, that the dumping is happening in the country."
Capital Allocation & Capacity Discipline
- DMC expansion deliberately deferred: Despite customer requests to invest in additional carbonates, management is "a little optimistic" and wants to see those customers come on stream before committing further capex, citing the lesson of existing DMC capacity running at only 20–30% versus 80–90% projections.
- Strategy prioritizes value over volume: The company is not limiting itself to increasing manufacturing capacities; it is focusing on moving toward higher-value products, strengthening backward integration, developing indigenous manufacturing processes, and improving overall quality of earnings.
- Three-pillar growth framework articulated: (1) Core amines and derivatives providing the operating foundation with focus on volumes, customer relationships and manufacturing efficiencies; (2) Newly commissioned Acetonitrile and DME facilities offering value-added and import-substitution opportunities with immediate priority on customer base establishment and stabilization; (3) Balaji Specialty Chemicals expansion broadening the specialty portfolio into additional products and end-user industries.
- Balaji Specialty Chemicals turned profitable: The subsidiary showed some profit this quarter, marking an operational milestone ahead of the brownfield and greenfield capacity additions.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Acetonitrile volume ramp | Minimum 1,000–1,200 tons per month from expanded 1,440 tons/month capacity | From December FY27, subject to market acceptance |
| DMC/PC deliveries | 500–1,000 tons per quarter to a named client | From next month onwards |
| Brownfield Unit-1 first product | EDA-based derivatives (DETA, TETA, Piperazine, AEEA, AEP) enter market | January FY27; delay in 1–2 equipment items could push to Feb/Mar 1st week |
| BSCL Unit-2 greenfield commissioning | Hydrogen cyanide, sodium cyanide, EDTA, EDTA-2Na | Q4 FY27 |
| NMM commercialization | N-Methyl Morpholine project | During FY27 |
| All capex completion | All expansions and capital investment closed | By end of FY27 |
| DME Road Tankers approval | Bulk domestic supply enablement | Next 3–4 weeks |
| EDA antidumping litigation | Writ petition in High Court | Filing within 1 month |
| DME capacity utilization (conditional) | \>90% if BPCL blending approval received; otherwise at least 50–55% | Next year (FY28) |
| All-plant utilization target | maximum 80–90% capacity utilization across plants | From Q1 FY28 |
| Topline aspiration | ₹3,500–4,000 crores | FY28–29, contingent on all expansions commencing production by FY27-end |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹472 crores, +36% YoY and +2% QoQ |
| Standalone revenue | ₹434 crores |
| Consolidated EBITDA | ₹106 crores, +58% YoY; -12% QoQ |
| Standalone EBITDA | ₹103 crores |
| EBITDA margin | 22%, vs 19% in Q2 FY26 and 26% in Q1 FY27 |
| Profit after tax | ₹67 crores, +82% YoY |
| Standalone PAT | ₹69 crores |
| Diluted EPS | ₹20.76 per equity share, vs ₹10.67 in Q2 FY26 |
| H1 FY27 consolidated revenue | ₹933 crores, +31% YoY |
| H1 FY27 consolidated EBITDA | ₹227 crores, +74% YoY; margin 24% vs 18% in H1 FY26 |
| H1 FY27 consolidated PAT | ₹146 crores, +98% YoY |
| Consolidated sales volumes | 24,491 metric tons, -6% YoY and +13.5% QoQ |
| Volume mix: Amines | 6,525 metric tons |
| Volume mix: Amines Derivatives | 8,974 metric tons |
| Volume mix: Specialty Chemicals | 8,992 metric tons |
| H1 FY27 consolidated sales volumes | 46,078 metric tons, vs 53,735 metric tons in H1 FY26 |
| Acetonitrile expanded capacity | 1,440 tons per month, commercial production commenced |
| Acetonitrile current price | ₹230–240 per kg |
| Acetonitrile expected production from Dec 2026 | 1,000 to 1,200 tons per month minimum |
| DME pricing | ₹90–100 per kg, driven by elevated methanol prices |
| DME ISO tanks exported in Q2 | 7 to 8 tanks on a repeated basis for aerosol application |
| DMF capacity utilization | more than 50%, up from 30–40% earlier |
| DMF current basic price | more than ₹110–115 |
| Methylamine Unit-4 utilization | 15–20% |
| EDA capacity utilization | 50–60% |
| DMC/PC client order this quarter | 500 to 1,000 tons, up from 20–60 tons earlier |
| Consolidated net worth | ₹2,083.02 crores as of Sep 30, 2026, vs ₹1,976.46 crores as of Mar 31, 2026 |
| Consolidated debt | ₹161.15 crores as of Sep 30, 2026 |
| Cash and cash equivalents | ₹52.62 crores as of Sep 30, 2026 |
| H1 FY27 cash flow from operations | ₹54.46 crores |
| H1 FY27 capex cash outflow | ₹99.38 crores |
| Standalone debt | Zero |
| Medium-term topline aspiration | ₹3,500–4,000 crores by FY28–29 |
| DME utilization next year with LPG blending approval | more than 90% |
| DME utilization next year without LPG blending | at least 50–55% |